ArticleTechnology in cancer research & treatment
The Potential for Enhanced Ovarian Cancer Diagnostics Through Optimized Derivative Magnetic Resonance Spectroscopy.
Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IntroductionOvarian cancer is a major global concern. Due to late detection, it is one of the few malignancies for which the five-year survival rate continues to be low without appreciable improvement in recent decades. Screening methods are needed that non-invasively, without ionizing radiation, detect early-stage ovarian cancer with clear distinction from benign lesions. Magnetic resonance spectroscopy (MRS) could be a key contributor to early ovarian cancer detection, insofar as data analysis and interpretation after appropriate signal processing are implemented.MethodsThe derivative non-parametric and parametric fast Padé transform (dFPT) and the derivative fast Fourier transform (dFFT: optimized, unoptimized) are applied to proton MRS time signals encoded from the ovary. These include in vivo MRS for a borderline cyst, and in vitro MRS for serous cystic adenoma and serous cystic adenocarcinoma.ResultsOn a broad chemical shift axis (aliphatic and aromatic), over 300 thin, clearly-delineated peaks are baseline-resolved and displayed in a readily amenable form for clinical interpretation. This is from the in vivo encoding. Clearly quantifiable peaks include cancer biomarkers: total choline components (phosphocholine, glycerophosphocholine, free choline) and the lactate doublet, as well as other diagnostically-relevant metabolites in spectrally-crowded regions. Concordance among three algorithms (parametric and non-parametric dFPT as well as optimized dFFT) provides cross-validation, essential for clinical trustworthiness of derivative MRS.ConclusionWith these results that help benchmark derivative MRS for clinical applications in oncology, the time is deemed ripe to implement the stated advances. More effective early detection of ovarian cancer should be among the most urgent priorities for this upgrade.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.